Krishanu Saha, Erik J Sontheimer, P J Brooks, Melinda R Dwinell, Charles A Gersbach, David R Liu, Stephen A Murray, Shengdar Q Tsai, Ross C Wilson, Daniel G Anderson, Aravind Asokan, Jillian F Banfield, Krystof S Bankiewicz, Gang Bao, Jeff W M Bulte, Nenad Bursac, Jarryd M Campbell, Daniel F Carlson, Elliot L Chaikof, Zheng-Yi Chen, R Holland Cheng, Karl J Clark, David T Curiel, James E Dahlman, Benjamin E Deverman, Mary E Dickinson, Jennifer A Doudna, Stephen C Ekker, Marina E Emborg, Guoping Feng, Benjamin S Freedman, David M Gamm, Guangping Gao, Ionita C Ghiran, Peter M Glazer, Shaoqin Gong, Jason D Heaney, Jon D Hennebold, John T Hinson, Anastasia Khvorova, Samira Kiani, William R Lagor, Kit S Lam, Kam W Leong, Jon E Levine, Jennifer A Lewis, Cathleen M Lutz, Danith H Ly, Samantha Maragh, Paul B McCray, Todd C McDevitt, Oleg Mirochnitchenko, Ryuji Morizane, Niren Murthy, Randall S Prather, John A Ronald, Subhojit Roy, Sushmita Roy, Venkata Sabbisetti, W Mark Saltzman, Philip J Santangelo, David J Segal, Mary Shimoyama, Melissa C Skala, Alice F Tarantal, John C Tilton, George A Truskey, Moriel Vandsburger, Jonathan K Watts, Kevin D Wells, Scot A Wolfe, Qiaobing Xu, Wen Xue, Guohua Yi, Jiangbing Zhou
The move from reading to writing the human genome offers new opportunities to improve human health. The United States National Institutes of Health (NIH) Somatic Cell Genome Editing (SCGE) Consortium aims to accelerate the development of safer and more-effective methods to edit the genomes of disease-relevant somatic cells in patients, even in tissues that are difficult to reach. Here we discuss the consortium's plans to develop and benchmark approaches to induce and measure genome modifications, and to define downstream functional consequences of genome editing within human cells...
April 2021: Nature